
## Zhenlei Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1815740/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development and validation of a rapid and sensitive UPLC–MS/MS method for quantification of kukoamine B in human plasma: Application to a clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2017, 132, 1-6.	2.8	14
2	Firstâ€inâ€patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 3053-3060.	3.8	13
3	Effect of Food on the Pharmacokinetic and Pharmacodynamic Profiles of Hetrombopag in Healthy Volunteers. Clinical Therapeutics, 2020, 42, 2280-2288.	2.5	10
4	Pharmacokinetics of Ginsenoside Rh2, the Major Anticancer Ingredient of Ginsenoside H Dripping Pills, in Healthy Subjects. Clinical Pharmacology in Drug Development, 2021, 10, 669-674.	1.6	8
5	Development and validation of a UPLC–MS/MS method for simultaneous determination of fotagliptin and its two major metabolites in human plasma and urine. Bioanalysis, 2017, 9, 381-393.	1.5	7
6	Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1667-1678.	3.6	3
7	Pharmacokinetics and Safety of Erenumab after a Single Subcutaneous Injection Dose in Healthy Chinese Subjects. Clinical Drug Investigation, 0, , .	2.2	3
8	Ultra performance liquid chromatography tandem mass spectrometry assay for determination of kukoamine B in human blood and urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1031, 8-14.	2.3	2
9	Pharmacokinetics and safety of tiotropium+olodaterol 5 μg/5Âμg fixed-dose combination in Chinese patients with COPD. Pulmonary Pharmacology and Therapeutics, 2020, 63, 101944.	2.6	2
10	First-in-human safety, tolerability, and pharmacokinetics of SY-007, a prolonged action neuroprotective drug for ischemic stroke, in healthy Chinese subjects. European Journal of Pharmaceutical Sciences, 2022, 170, 106104.	4.0	2
11	A UPLC–MS/MS method for quantification of 5α-androst-3β,5,6β-triol in human plasma: development, validation and its application in clinical pharmacokinetic study. Bioanalysis, 2017, 9, 873-885.	1.5	1
12	An ultra HPLC–MS/MS method for quantification of hypidone hydrochloride (YL-0919) and application to a pharmacokinetic study. Bioanalysis, 2019, 11, 1243-1254.	1.5	1
13	Development and validation of a UPLC–MS/MS method for quantification of C-005, a novel third-generation EGFR TKI, and its major metabolite in plasma: Application to its first-in-patient study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1162, 122475.	2.3	1
14	LC–MS/MS assay for the determination of tatâ€K13, a novel interfering peptide for the treatment of ischemic stroke, in human plasma and its application to a pharmacokinetics study. Biomedical Chromatography, 2021, 35, e5095.	1.7	1
15	Impact of targetâ€mediated drug disposition on hetrombopag pharmacokinetics and pharmacodynamics in Chinese healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. British Journal of Clinical Pharmacology, 2021	2.4	1